Safety outcomes: examined odds of hypoglycemic events using administrative codes validated in prior studies 55,56 and gastrointestinal symptoms (constipation, diarrhea, change in bowel habits, abdominal pain, or ileus) during follow up period using administrative codes, as described in prior publications 57
Christian Isalomboto Nkanga, Jean Paul Nzundu Mbo, Priscille Mbemba Mulosi, and Jos Mbemba Kiniema for their contribution
10 mg vial + 3.0 mL BAC water (about 3.33 mg/mL) Draw (units) 7.5 units Volume 0.075 mL Amount delivered about 0.25 mg (250 mcg) Draw (units) 10 units Volume 0.10 mL Amount delivered about 0.33 mg (333 mcg) Draw (units) 11.25 units Volume 0.1125 mL Amount delivered about 0.375 mg (375 mcg) Draw (units) 15 units Volume 0.15 mL Amount delivered about 0.5 mg (500 mcg) Draw (units) 30 units Volume 0.30 mL Amount delivered about 1.0 mg (1,000 mcg) Amounts are rounded
Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist that has generated questions about potential effects on sexual function
For noticeable skin brightening effects, most people require 8 to 12 glutathione injection sessions